NCT03177187 - Combination Study of AZD5069 and Enzalutamide. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

September 15, 2022

Study Completion Date

November 16, 2022

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

AZD5069

10mg and 40mg plain, beige, film-coated tablets packaged in bottles

DRUG

Enzalutamide 40 MG

Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).

Trial Locations (4)

Unknown

Bellinzona Hospital, Bellinzona

University Hospital Southampton, Southampton

BT9 7AB

Belfast City Hospital, Belfast

SM2 5PT

The Royal Marsden Hospital Foundation Trust, Sutton